Post by Oncode Accelerator

Too often, promising oncology drug candidates advance through early development… Only to reveal dangerous off-target effects or unexpected toxicities during clinical studies. One powerful way to prevent this is to generate richer and more biologically relevant data earlier in the preclinical pipeline – for instance by using Omivera’s CellEKT technology. Read more in this article about one of the newest partners in our oncology ecosystem, and what they have to offer 👉 https://lnkd.in/eBUTRrJY Joel Rüegger, Anthe Janssen, Zoë Vogelaar #smallmolecules #drugdevelopment #kinaseinhibitor #oncology